65. Primary immunodeficiency Clinical trials / Disease details
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-004518-28-GB (EUCTR) | 08/12/2009 | 09/11/2009 | Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD | Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD | Children with chronic granulomatous disease (CGD). MedDRA version: 9.1;Level: LLT;Classification code 10008906;Term: Chronic granulomatous disease | Trade Name: Noxafil 40 mg/ml oral solution Product Name: noxafil INN or Proposed INN: POSACONAZOLE | Radboud University Nijmegen Medical Centre | NULL | Not Recruiting | Female: yes Male: yes | 20 | United Kingdom;Netherlands | |||
| 2 | EUCTR2008-004518-28-NL (EUCTR) | 19/11/2008 | 24/11/2008 | Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD | Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD | Children with chronic granulomatous disease (CGD). MedDRA version: 9.1;Level: LLT;Classification code 10008906;Term: Chronic granulomatous disease | Trade Name: Noxafil 40 mg/ml oral solution | Radboud University Nijmegen Medical Centre | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom;Netherlands |